EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. - MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKIN

On Feb 5, 2026, Department of Health and Human Services obligated $118,563,679 to EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. for medical countermeasures (mcm) that can be deployed in the event of a filovirus outbreak are a crucial component to the united states government?s (usg?s) outbreak response plan. biomedical advanced re…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 2 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in GAITHERSBURG, MD. The contract is scheduled through Jul 29, 2033. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.